wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q46889307-7AFAB5DE-D3A2-4CD6-8C41-1C97207B46A3
Q46889307-7AFAB5DE-D3A2-4CD6-8C41-1C97207B46A3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q46889307-7AFAB5DE-D3A2-4CD6-8C41-1C97207B46A3
YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.
P2860
Q46889307-7AFAB5DE-D3A2-4CD6-8C41-1C97207B46A3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q46889307-7AFAB5DE-D3A2-4CD6-8C41-1C97207B46A3
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
dfa82128324211974cc590c6d51bde4a6263ca21
P2860
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.